Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (62)	5/18/1999 9:14:00 AM
From: scaram(o)uche	Respond to of 362

this is what the company is reporting for TriGem....... biz.yahoo.com The Company reported that 40 of 47 patients generated strong, anti- cancer immune responses following administration of TriGem. Preliminary clinical responses were encouraging, with a complete clinical response in one patient, who remains without evidence of disease for a period of 18 months, and 17 additional patients with stable disease for periods ranging from 10-36 months. The median survival has not been reached for the total patient population or for the 26 patients with soft tissue disease. For the 18 patients with visceral metastases, the median survival was 15 months. ''These survival results compare quite well to that seen in previously published reports with other drug regimens in these patients,'' commented Dr. Ken Foon, Director of the Barrett Center for Prevention, Treatment and Research at the University of Cincinnati, who presented this data at ASCO. ''TriGem appears to have a favorable positive impact on disease progression and survival.''

To: BRAVEHEART who wrote (62)	5/18/1999 9:17:00 AM
From: scaram(o)uche	Respond to of 362

this is what the company is reporting for TriAb....... biz.yahoo.com TriAb was administered on a weekly basis for three weeks, starting one week after chemotherapy, and then continued monthly following stem cell transplantation for up to 24 months. A strong immune response against the breast cancer antigen, HMFG, was demonstrated in 20 of 21 patients. Seventeen patients have no evidence of disease progression at a median of 4 months (range 1-12 months). None of the treated patients experienced any significant adverse effects from treatment with the vaccine. ''Titan has previously demonstrated that its cancer vaccines can be used in conjunction with other current standard treatments, such as chemotherapy with 5FU, leucovorin, or irinotecan for colon cancer, and radiation therapy for lung cancer,'' explained Dr. April Teitelbaum, Sr. Director of Clinical Research at Titan. ''In patients with impaired immune systems, this can be potentially challenging. The swift generation of anti-HMFG cancer antigen immune responses by TriAb in patients following bone marrow transplantation, which typically suppresses the immune system, is therefore quite impressive.''

To: BRAVEHEART who wrote (62)	5/18/1999 9:19:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 362

status update on Pivanex and CeaVac....... biz.yahoo.com Titan's third anti-cancer vaccine, CeaVac(tm), is being tested in a 200 patient multi-center, placebo controlled, randomized Phase II study in the U.S. and the U.K. for treatment of metastatic colorectal cancer. Titan is also developing Pivanex(tm), an analog of butyric acid, which attacks cancer cells through the mechanism of cellular differentiation. In Phase I testing, Pivanex demonstrated anti-tumor activity in a patient with squamous cell lung cancer, and also demonstrated possible stabilization of disease, with improved performance status, in a patient with thymoma refractory to multiple therapies. Based on these encouraging results, Titan is conducting a Phase II study with Pivanex in non-small cell lung cancer patients.